Immix Biopharma (IMMX) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$0.22
- EPS estimate
- −$0.16
- EPS surprise
- −37.50%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Aug 8, 2025
Immix Biopharma reported its Q2 2025 results on August 8, 2025. The company posted a loss of $0.22 per share, wider than the $0.16 loss analysts expected, a miss of 37.50%. A year earlier, in Q2 2024, the loss was $0.15 per share. No revenue was reported for the quarter, and none appears anywhere in the table.
The record is short and has gaps: seven quarters from Q3 2023 to Q2 2025, with Q4 2023 missing. Every quarter shown was a loss, ranging from $0.15 to $0.24 per share. The four quarters of 2024 add up to a loss of $0.80 per share. The first half of 2025 lost $0.37 per share, close to the $0.38 lost in the first half of 2024. Against estimates, results were mixed: two beats, two misses and three quarters exactly in line. The largest miss was Q3 2024, at 50.00%, and the largest beat Q1 2025, at 34.78%.
The table shows no report after Q2 2025. In the period covered, Immix reported second-quarter results in August and third-quarter results in mid-November. Newer figures will show whether the losses stay in the same range seen over the past two years.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 8, 2025 | −$0.16 | −$0.22 | −37.50% | $0.00 | SEC |
| Q1 2025 | May 8, 2025 | −$0.23 | −$0.15 | +34.78% | $0.00 | SEC |
| Q4 2024 | Mar 25, 2025 | −$0.25 | −$0.18 | +28.00% | $0.00 | SEC |
| Q3 2024 | Nov 12, 2024 | −$0.16 | −$0.24 | −50.00% | $0.00 | SEC |
| Q2 2024 | Aug 12, 2024 | −$0.15 | −$0.15 | +0.00% | $0.00 | SEC |
| Q1 2024 | May 9, 2024 | −$0.23 | −$0.23 | +0.00% | $0.00 | SEC |
| Q3 2023 | Nov 13, 2023 | −$0.23 | −$0.23 | +0.00% | $0.00 | SEC |
Quarterly revenue
Frequently asked questions
When did Immix Biopharma (IMMX) last report earnings?
Immix Biopharma last reported on Aug 8, 2025, covering fiscal Q2 2025.
Did IMMX beat earnings estimates?
No. Immix Biopharma reported EPS of −$0.22 for Q2 2025 against a −$0.16 estimate — a 37.50% miss.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.